|
1
|
Zhao C, Hao M, Bian T, Zhao X, Chi X, Chen Z, Fu G, Zhu Z, Fang T, Yu C, Li J, Chen W. Screening of Neutralizing Antibodies Targeting Gc Protein of RVFV. Viruses 2025; 17:559. [PMID: 40285002 PMCID: PMC12031069 DOI: 10.3390/v17040559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2025] [Revised: 04/06/2025] [Accepted: 04/07/2025] [Indexed: 04/29/2025] Open
Abstract
Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that can cause substantial morbidity and mortality in livestock and humans, for which there are no currently available licensed human therapeutics or vaccines. Therefore, the development of safe and effective antivirals is both necessary and urgent. The Gc protein is the primary target of the neutralizing antibody response related to Rift Valley fever virus. Here, we report one Gc-specific neutralizing antibody (NA137) isolated from an alpaca and one bispecific antibody (E2-NA137), the protective efficacies of which we evaluated in A129 mice. In this prophylactic study, the survival rates of the NA137 and E2-NA137 groups were both 80%, and in the treatment study, the survival rates were 20% and 60%, respectively. Altogether, our results emphasize that NA137 and E2-NA137 provide a potential approach for treating RVFV either prophylactically or therapeutically.
Collapse
Affiliation(s)
- Chuanyi Zhao
- School of Medicine, Zhejiang University, Hangzhou 310058, China;
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Meng Hao
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Ting Bian
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Xiaofan Zhao
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Xiangyang Chi
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Zhengshan Chen
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Guangcheng Fu
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Zheng Zhu
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Ting Fang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Changming Yu
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Jianmin Li
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| | - Wei Chen
- School of Medicine, Zhejiang University, Hangzhou 310058, China;
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (M.H.); (T.B.); (X.Z.); (X.C.); (Z.C.); (G.F.); (Z.Z.); (T.F.); (C.Y.)
| |
Collapse
|
|
2
|
Guo J, Lu J, Du P, Cheng K, Lei C, Jiang Y, Peng M, Li Y, Sun K, Xu C, Yu Y, Gao C, Kang Q, Zhang Y, Wang R, Yang Z. Fluorescence Reduction Neutralization Test: A Novel, Rapid, and Efficient Method for Characterizing the Neutralizing Activity of Antibodies Against Dengue Virus. Curr Issues Mol Biol 2025; 47:140. [PMID: 40136394 PMCID: PMC11941698 DOI: 10.3390/cimb47030140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2025] [Revised: 02/10/2025] [Accepted: 02/19/2025] [Indexed: 03/27/2025] Open
Abstract
Dengue virus (DENV) is a major public health threat in the tropical and subtropical regions of the world. Climate change resulting from global warming is further expanding DENV-endemic areas, adversely affecting public life and health. Despite this, no specific drug against DENV has been developed so far. Vaccines and neutralizing antibodies are the chief preventive and therapeutic tools for managing pathogenic infections. The present study describes the development of a novel fluorescence reduction neutralization test (FRNT) for evaluating the neutralizing activity of antibodies against DENV. This FRNT allows rapid antibody screening. In addition, we calculated the FRNT50 to indicate the neutralizing ability of the antibodies. In contrast to the conventional plaque reduction neutralization assay, the FRNT has a shorter experimental cycle, a simpler operation, and greater objectivity, which can greatly accelerate the research and development process of vaccines and antibodies against DENV.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - Rong Wang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (J.G.); (J.L.); (P.D.); (K.C.); (C.L.); (Y.J.); (M.P.); (Y.L.); (K.S.); (C.X.); (Y.Y.); (C.G.); (Q.K.); (Y.Z.)
| | - Zhixin Yang
- Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing 100071, China; (J.G.); (J.L.); (P.D.); (K.C.); (C.L.); (Y.J.); (M.P.); (Y.L.); (K.S.); (C.X.); (Y.Y.); (C.G.); (Q.K.); (Y.Z.)
| |
Collapse
|
|
3
|
Ma Z, Guo J, Jiang L, Zhao S. Lateral flow immunoassay (LFIA) for dengue diagnosis: Recent progress and prospect. Talanta 2024; 267:125268. [PMID: 37813013 DOI: 10.1016/j.talanta.2023.125268] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 09/22/2023] [Accepted: 10/01/2023] [Indexed: 10/11/2023]
Abstract
Dengue is one of the most widespread and fatal arboviral infections in the world. Early detection of dengue virus (DENV) is essential to prevent the spread of the disease and provide an immediate response. The lateral flow immunoassay (LFIA) systems are low-cost, rapid, sensitive, targeted, and straightforward detection, which is an ideal early detection candidate for point-of-care testing (POCT) in dengue-affected areas. However, current commercial LFIA kits cannot fully satisfy the sensitivity, specificity, serotype differentiation, and multiplex detection requirements. Therefore, various strategies have been applied to optimize the LFIA for DENV detection, including label material improvement, optical enhancement and novel structure design. In this review, we comprehensively presented the snapshot of dengue, the principle of LFIA, and recent progress in the LFIA optimization for dengue diagnoses. Furthermore, this review also discusses insights into the prospect of LFIA dengue diagnostic methods, such as microfluidics, multiplex design, nucleic acid-typed probes and smartphone-assisted result analysis.
Collapse
Affiliation(s)
- Ziting Ma
- Department of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong, 510006, China
| | - Jinnian Guo
- Department of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong, 510006, China
| | - Lu Jiang
- Department of Biomedical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong, 510006, China.
| | - Suqing Zhao
- Department of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, Guangdong, 510006, China.
| |
Collapse
|
|
4
|
Wang R, Guo J, Lu J, Du P, Zhang J, Yu Y, Chen L, Xiong Z, Xiang Y, Ni X, Xu J, Yang Z. A potential broad-spectrum neutralizing antibody against Betacoronavirus. J Med Virol 2023; 95:e29252. [PMID: 38078658 DOI: 10.1002/jmv.29252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 10/13/2023] [Accepted: 11/10/2023] [Indexed: 12/18/2023]
Abstract
Three pandemics caused by human Betacoronavirus had broken out in the past two decades. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was one of the novel epidemic strains which caused the third pandemic, coronavirus disease 2019 (COVID-19), a global public health crisis. So far, more than millions of people have been infected. Considering the public health and economic impact of Betacoronavirus pandemic, drugs with broad-spectrum activity against these coronaviruses are urgently needed. In this study, two monoclonal antibodies targeting SARS-CoV-2 spike protein receptor-binding domain (RBD) with good neutralizing activity were used to construct a novel immunoglobulin-like bispecific antibody BI31. The neutralizing effect of BI31 against the pseudovirus and the authentic virus is better than that of its parent antibodies alone and in combination. What surprised us most was that the newly constructed bispecific antibody also had the neutralizing activity against SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) that the parent antibodies did not have. These suggested that the BI31 can not only be developed as a therapeutic drug against COVID-19 but it could also become a broad-spectrum therapeutic antibody against Betacoronavirus.
Collapse
Affiliation(s)
- Rong Wang
- Beijing Institute of Biotechnology, Beijing, China
| | - Jiazheng Guo
- Beijing Institute of Biotechnology, Beijing, China
| | - Jiansheng Lu
- Beijing Institute of Biotechnology, Beijing, China
| | - Peng Du
- Beijing Institute of Biotechnology, Beijing, China
| | - Jun Zhang
- Beijing Institute of Biotechnology, Beijing, China
| | - YunZhou Yu
- Beijing Institute of Biotechnology, Beijing, China
| | - Lei Chen
- Beijing Institute of Biotechnology, Beijing, China
| | | | | | - Xiaodan Ni
- Shuimu BioSciences Co., Ltd, Beijing, China
| | - Junjie Xu
- Beijing Institute of Biotechnology, Beijing, China
| | - Zhixin Yang
- Beijing Institute of Biotechnology, Beijing, China
| |
Collapse
|
|
5
|
Lu J, Jiang Y, Guo J, Chen L, Liu F, Li Z, Liu X, Du P, Yu Y, Wang R, Yang Z. A human bispecific antibody neutralizes botulinum neurotoxin serotype A. Sci Rep 2023; 13:20806. [PMID: 38012220 PMCID: PMC10681988 DOI: 10.1038/s41598-023-48008-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 11/21/2023] [Indexed: 11/29/2023] Open
Abstract
Botulinum neurotoxin (BoNT) shows high lethality and toxicity, marking it as an important biological threat. The only effective post-exposure therapy is botulinum antitoxin; however, such products have great potential for improvement. To prevent or treat BoNT, monoclonal antibodies (mAbs) are promising agents. Herein, we aimed to construct a bispecific antibody (termed LUZ-A1-A3) based on the anti-BoNT/A human monoclonal antibodies (HMAb) A1 and A3. LUZ-A1-A3 binds to the Hc and L-HN domains of BoNT/A, displaying potent neutralization activity against BoNT/A (124 × higher than that of HMAb A1 or HMAb A3 alone and 15 × higher than that of the A1 + A3 combination). LUZ-A1-A3 provided effective protection against BoNT/A in an in vivo mouse model. Mice were protected from infection with 500 × LD50 of BoNT/A by LUZ-A1-A3 from up to 7 days before intraperitoneal administration of BoNT/A. We also demonstrated the effective therapeutic capacity of LUZ-A1-A3 against BoNT/A in a mouse model. LUZ-A1-A3 (5 μg/mouse) neutralized 20 × LD50 of BoNT/A at 3 h after intraperitoneal BoNT/A administration and complete neutralized 20 × LD50 of BoNT/A at 0.5 h after intraperitoneal BoNT/A administration. Thus, LUZ-A1-A3 is a promising agent for the pre-exposure prophylaxis and post-exposure treatment of BoNT/A.
Collapse
Affiliation(s)
- Jiansheng Lu
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Yujia Jiang
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Jiazheng Guo
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Lei Chen
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Fujia Liu
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Zhiying Li
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Xuyang Liu
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Peng Du
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China
| | - Yunzhou Yu
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
| | - Rong Wang
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
| | - Zhixin Yang
- Laboratory of Protein Engineering, Beijing Institute of Biotechnology, Beijing, China.
| |
Collapse
|